Evoke Pharma, Inc.
12671 High Bluff Drive
Suite 200
San Diego
California
92130
United States
Tel: 858-967-5454
Website: http://www.evokepharma.com/
171 articles about Evoke Pharma, Inc.
-
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
3/21/2024
Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases with an emphasis on GIMOTI® nasal spray, announced that Matthew J. D’Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer’s departure for personal reasons.
-
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
3/14/2024
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and recent corporate developments.
-
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
3/7/2024
Evoke Pharma, Inc. (NASDAQ: EVOK) today announced that the Company is scheduled to release its fourth quarter and full year 2023 on Thursday, March 14, 2024, after the market closes.
-
Evoke Pharma Announces Closing of $7.5 Million Public Offering
2/14/2024
Evoke Pharma, Inc. announced today that it has closed an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 million.
-
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
2/9/2024
Evoke Pharma, Inc. announced today that it has priced an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 million, that includes initial upfront funding of approximately $7.5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.
-
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
11/27/2023
Evoke Pharma, Inc. announced that its recently issued U.S. patent related to GIMOTI, No. 11,813,231 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Therapeutic Equivalence Evaluations”, commonly known as the “Orange Book”.
-
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
11/14/2023
Evoke Pharma, Inc. announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI.
-
Evoke Pharma Reports Third Quarter 2023 Financial Results
11/9/2023
Evoke Pharma, Inc. announced its financial results for the third quarter ended September 30, 2023, and recent corporate developments.
-
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023
10/31/2023
Evoke Pharma, Inc. and EVERSANA announced a summary of real-world data on the positive impact of GIMOTI usage in reducing healthcare costs for patients suffering from diabetic gastroparesis versus patients taking oral metoclopramide.
-
Evoke Pharma’s Abstract is to Be Presented at The American College of Gastroenterology (ACG) 2023
10/18/2023
Evoke Pharma, Inc. announced that its real-world healthcare utilization data will be presented, as an oral plenary presentation, at the American College of Gastroenterology annual meeting taking place in Vancouver, BC, Canada from October 20-25, 2023.
-
Evoke Pharma Reports Second Quarter 2023 Financial Results
8/10/2023
Evoke Pharma, Inc. announced its financial results for the second quarter ended June 30, 2023, and recent corporate developments.
-
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
8/7/2023
Evoke Pharma, Inc. EVERSANA™, a leading provider of global commercial services to the life science industry, announced that its abstract entitled “Nasal Metoclopramide Reduces Healthcare Visits in Diabetic Gastroparesis Patients With and Without Prior Oral Metoclopramide History” will be presented in a poster session at the American Neurogastroenterology and Motility Society (ANMS) Annual Meeting being held August 11-13, 2023 in Austin, Texas.
-
Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting
7/25/2023
Evoke Pharma, Inc. today announced that its abstract entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” will be presented, as an oral plenary presentation, at the American College of Gastroenterology annual meeting taking place in Vancouver, BC, Canada from October 20-25, 2023.
-
Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment
6/14/2023
Evoke Pharma, Inc. announced that it will host a key opinion leader webinar on June 22, 2023 at 11:00am ET to discuss the healthcare resource utilization data related to GIMOTI usage presented in a plenary session at DDW 2023 annual conference.
-
Evoke Pharma Reports First Quarter 2023 Financial Results
5/15/2023
Evoke Pharma, Inc. (NASDAQ: EVOK) today announced its financial results for the first quarter ended March 31, 2023, and recent corporate developments.
-
Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources
5/9/2023
Evoke Pharma, Inc., and EVERSANA™ announced the details of its presentation at Digestive Disease Week 2023 demonstrating that GIMOTI reduces healthcare resource utilization for patients with diabetic gastroparesis versus patients on oral metoclopramide.
-
Evoke Adds Industry Veteran Cheryl Fielding as Chief Client Officer
5/4/2023
Evoke, an Inizio company and leading global health brand, experience, and communications platform, announced the appointment of Cheryl Fielding as Chief Client Officer.
-
Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023
5/4/2023
Evoke Pharma, Inc. (NASDAQ: EVOK) announced that the abstract entitled “Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide” will be presented at Digestive Disease Week (DDW) 2023 taking place from May 6-9, 2023 at the McCormick Place, Chicago.
-
New GIMOTI Patent Listed in FDA Orange BookBroad Formulation Patent Expands Protection for Gimoti
5/1/2023
Evoke Pharma, Inc. (NASDAQ: EVOK) announced that its recently issued U.S. patent related to GIMOTI, No. 11,628,150 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Therapeutic Equivalence Evaluations”, commonly known as the “Orange Book”.
-
United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTIThe Company Will Submit for FDA Orange-Book Listing in the Near Term
4/20/2023
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,628,150 under the title “Nasal Formulations of Metoclopramide.”